An antihypertensive intervention trial to lower blood pressure in untreated hypertensive patients based on the gene polymorphisms in the pathway of the drug-metabolism and biological effects
Completed
- Conditions
- HypertensionCardiovascular - Hypertension
- Registration Number
- ACTRN12607000108415
- Lead Sponsor
- Cardiovascular Institute, Chinese Academy of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 4000
Inclusion Criteria
Untreated hypertensive patients, including those with newly diagnosed hypertension ( systolic/diastolic blood pressure >=160/95mmHg at two visits), and those with history of hypertension but not receiving antihypertensive treatment for at least 8 weeks (systolic/diastolic blood pressure >=140/90mmHg at two visits).
Exclusion Criteria
Secondary hypertension; contraindication to any studied drugs; serum potassium values<3.5mEq/L or >5.5mEq/L at screening stage; requirement for any study drugs for reasons other than hypertension; low likelihood of compliance with protocol (eg, dementia, substance abuse); and a history of any severe, life-threatening disease within the past 3 years.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Office blood pressure reponse[From baseline to 8 weeks, including measurement at 2 and 4 weeks.]
- Secondary Outcome Measures
Name Time Method Side effects were observed at 2 weeks and 4 weeks after drug treatment.[]